ZLAB Zai Lab Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZLAB

Price (delayed)

$26.44

Market cap

$2.97B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.8

Enterprise value

$2.52B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25
Highlights
Zai Lab's revenue has increased by 5% YoY
The company's net income rose by 11% YoY but it fell by 6% QoQ
The EPS has grown by 10% YoY but it has contracted by 6% from the previous quarter
The quick ratio is down by 35% year-on-year and by 12% since the previous quarter
The debt has grown by 33% YoY and by 10% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.zailaboratory.com
Peers: OPK ORGO

Key stats

What are the main financial stats of ZLAB

ZLAB stock price

How has the Zai Lab stock price performed over time
Intraday
0.11%
1 week
7.17%
1 month
1.65%
1 year
-17.56%
YTD
49.89%
QTD
39.16%

Financial performance

How have Zai Lab's revenue and profit performed over time
Revenue
$449.61M
Gross profit
$253.9M
Operating income
-$258.67M
Net income
-$188.21M
Gross margin
56.5%
Net margin
-41.9%
The net margin has grown by 16% YoY but it has contracted by 7% from the previous quarter
The company's net income rose by 11% YoY but it fell by 6% QoQ
The company's operating margin fell by 9% QoQ and by 3% YoY
The gross margin is down by 9% year-on-year and by 2.4% since the previous quarter

Price vs fundamentals

How does ZLAB's price correlate with its fundamentals

Growth

What is Zai Lab's growth rate over time

Valuation

What is Zai Lab stock price valuation
P/E
N/A
P/B
4.89
P/S
6.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.59
The EPS has grown by 10% YoY but it has contracted by 6% from the previous quarter
The stock's P/B is 40% above its 5-year quarterly average of 3.5 and 36% above its last 4 quarters average of 3.6
The equity has contracted by 23% YoY and by 8% from the previous quarter
ZLAB's price to sales (P/S) is 57% lower than its 5-year quarterly average of 15.4 but 19% higher than its last 4 quarters average of 5.5
Zai Lab's revenue has increased by 5% YoY

Efficiency

How efficient is Zai Lab business performance
Zai Lab's return on invested capital has decreased by 40% YoY and by 12% QoQ
The ROS has grown by 16% YoY but it has contracted by 7% from the previous quarter
ZLAB's ROE is down by 13% QoQ
The ROA has grown by 12% YoY but it has contracted by 8% from the previous quarter

Dividends

What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZLAB.

Financial health

How did Zai Lab financials performed over time
The total assets is 130% more than the total liabilities
The quick ratio is down by 35% year-on-year and by 12% since the previous quarter
The current ratio has contracted by 32% YoY and by 11% from the previous quarter
The debt is 58% less than the equity
Zai Lab's debt to equity has soared by 75% YoY and by 20% from the previous quarter
The debt has grown by 33% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.